翻译频道
登录注册网站首页

有人认为中国对病毒实施“零容忍”成本过高?钟南山:放任不管,成本会更高

来源:21英语网
作者:21ST
日期:2021-11-04
据央视新闻报道,近日,钟南山呼吸疾病防控创新团队,获2020年度国家科技进步奖创新团队奖。


视频来源:央视网

The research team headed by Zhong Nanshan, one of the country's leading pulmonologists who helped spearhead China's anti-COVID-19 efforts, received the 2020 State Scientific and Technological Progress Award's Innovation Team Award on Wednesday.

以钟南山、何建行、冉丕鑫为学术带头人的呼吸疾病防控团队自1979年建立以来,对影响我国居民健康的慢阻肺、 肺癌、SARS及COVID-19 等重大呼吸系统疾病的防、诊、治做出了重要贡献。

With nearly five decades of respiratory research and clinical experience between them, Zhong and two other team leaders, He Jianxin and Ran Pixi, led the group in working on many difficult respiratory ailments including severe acute respiratory syndrome (SARS), COVID-19, lung cancer and chronic obstructive pulmonary disease.

网友们纷纷发来祝福,钟老团队实至名归:


对于获奖,钟南山在接受CGTN采访时表示,这个奖项是极大地肯定了团队研究的方向:研究国家急需要的、最需要的东西。谈到未来的发展,他说,当前医学的战略正在从“以治疗为中心”调整为“以健康为中心”。他希望不同国家摒弃政治因素,各取所长,加强交流与合作。
 

图源:CGTN

当前,国内多地出现疫情反弹和零星病例,部分区域采取了管控措施,有越来越多的人接种了加强针。钟南山也在采访中回答了大家关注的热点问题。


视频来源:CGTN

本轮疫情何时得到有效控制?

钟南山表示,在中国强有力的监管、防控以及经验之下,有信心疫情在一个月内能得到有效控制。钟南山认为,中国在面对德尔塔时成功地总结了经验,包括确定零号病人,确定疫情传染链,精准筛查密切接触者,进行全员核酸检测以及隔离等。他说,广州以及南京都是在这种经验指导之下,一个月左右取得了疫情防控成功。

Zhong Nanshan said he is confident that sporadic outbreaks in China's northwestern and northeastern regions can be effectively controlled in about a month with government help. A local outbreak of the coronavirus in Guangzhou, Guangdong province, in May and June was controlled in about a month, while another outbreak reported in Nanjing, Jiangsu province, was tamped down within 26 days, he said.


图源:CGTN

钟南山表示,目前总结出了四点经验:

第一,是找出‘零号病人’;
第二是确定传染链;
第三是根据传染链找到密切接触者,以便能够精准地进行筛查;
第四,如果出现局部感染病例较多的情况,需要在局部地区进行全员检测以及及时的隔离。”

Zhong explained in an interview with CGTN on Monday how China had achieved such success. "The first is to find the first patient and trace where he or she came from. Second is to determine the infection chain," Zhong said. "Third is to find close contacts in the infection chain, so that they can be screened in a timely manner. And fourth is that all the close contacts are isolated and tested in time to prevent the coronavirus from spreading in local communities."

此外,钟南山表示,目前全国已有10亿多人接种了两针新冠疫苗,加强针接种应该继续增加,明年上半年形成较好群体免疫的可能性就比较大了。

Zhong Nanshan said herd immunity against COVID-19 is highly likely to happen in the country in the first half of 2022. This comes amid a massive drive to administer vaccine boosters.
 

11月2日,在南宁市青秀区方园社区卫生服务中心,医务人员给居民接种新冠疫苗加强针。 新华社记者 陆波岸 摄

“零传播”政策成本过高?

对于有人认为的中国对新冠疫情的“零病例”政策成本过高问题,钟南山表示,中国实施的“零容忍”或“零传播”政策是不得已而为之。因为病毒传播太迅速,复制指数太高,尽管现在已经有了疫苗,全世界范围内新冠肺炎的病死率还是达到了2%左右,“不能够容忍这么高的病死率”。 钟南山表示,“零传播”的政策的确成本较高,但是比起对病毒放任不管,成本还会更高。

Zhong said China had to introduce a zero-tolerance and zero-transmission policy, as the current Delta variant spreads fast. It replicates very quickly. Despite having vaccines against the coronavirus, the fatality rate with COVID-19 is still high and China can not tolerate that, he said. He admitted it's expensive to pursue a zero-transmission policy in the country, but he said "the cost is higher when we ignore it and let it spread".


11月1日,在哈尔滨市平房区一小区内,医务人员在为居民做核酸检测。新华社记者 王建威 摄

钟南山说,中国采用的是逐步放开的策略,现在的政策还是“零容忍”,可以称为持续性的“零感染”和“零传播”,而不是绝对性的“零传播”,“只要病毒一出现,就采取上述措施有效应对,以便把病毒控制在很小的范围内并把它控制住。”而至于会持续多长时间,钟南山表示:这有赖于世界、各地,看看全世界对它的防控情况,因为中国做得再好,只要是有开放、有输入的话肯定还会有传播。所以目前这样的情况下,零传播战略并不是成本过高,而是比较低成本的一个做法。

Zhong added that imported cases of COVID-19, or sporadic outbreaks, will certainly be reported in the country if China opens to the world in the months to come. Therefore, he said, he thought the policy would remain in place for a long time. Exactly how long must be judged on the basis of observing viral behavior and illnesses all over the world in coming months.

"No matter how well China does, there will be imported cases when the country opens its door. Therefore, under such circumstances, I think China's zero-tolerance strategy doesn't cost too much. It's a relatively low-cost approach," he said.

综合来源:CGTN,中国日报网,中国新闻网
分享到


联系我们  |  诚聘英才  |  演讲比赛  |  关于我们
© i21st.cn   京ICP备2024066071号-1